PIXUVRI

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug PIXUVRI contains one active pharmaceutical ingredient (API):

1	Pixantrone UNII P0R64C4CR9 - PIXANTRONE DIMALEATE
	Pixantrone is a cytotoxic aza-anthracenedione. Unlike approved anthracyclines (doxorubicin and others) and anthracenediones (mitoxantrone), pixantrone is only a weak inhibitor of topoisomerase II. Pixantrone is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell lymphomas (NHL).
	Read more about Pixantrone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PIXUVRI Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01DB11		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1582938
ES	Centro de información online de medicamentos de la AEMPS	112764001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	422323
FR	Base de données publique des médicaments	69454261
GB	Medicines & Healthcare Products Regulatory Agency	215169
IT	Agenzia del Farmaco	042463012
LT	Valstybinė vaistų kontrolės tarnyba	1066427
PL	Rejestru Produktów Leczniczych	100313180